A Phase 2 interventional study of Evolocumab and Placebo in Hypercholesterolemia and High Risk for Cardiovascular Events, sponsored by Amgen. Completed at 42 sites in Japan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-11-28.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing evolocumab in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. evolocumab · Hypercholesterolemia.
Among the 36 studies testing evolocumab in Hypercholesterolemia, this one is the 17th largest by enrollment, is one of 4 that started in 2012, is one of 5 in phase 2, and was the 8th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 36 studies testing evolocumab in Hypercholesterolemia is open now. Recruiting first, the newest first:
evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 20 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 24 · Phase 4 7
First in 2011; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 310 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 308 across the 36 interventional studies. Of the 32 that completed or were terminated, 31 (97%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 36 have an industry lead sponsor. The 6 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
35 studies in Hypercholesterolemia by Amgen: 1 open now, 1 under way, none of them phase 3. Of 34 finished, 30 (88%) have results posted.
Among the 35 studies in Hypercholesterolemia by Amgen, this one is the 17th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2012, is one of 5 in phase 2, and was the 8th registered.
Amgen’s Hypercholesterolemia studies by the year they started, since 2011.
None of the studies under way reaches primary completion within a year.
Among the 36 studies testing evolocumab in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 35 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective is to evaluate the effect of 12 weeks of subcutaneous evolocumab every 2 weeks or every 4 weeks, compared with placebo, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) when used in addition to statin therapy in Japanese adults with hypercholesterolemia and high cardiovascular risk.
Inclusion Criteria: Japanese adult, on statin, with or without ezetimibe, with stable dose(s) for at least 4 weeks, fasting LDL-C greater than or equal to 115 mg/dL (3.0 mmol/L), fasting triglycerides less than or equal to 400 mg/dL (4.5 mmol/L); Exclusion Criteria: (NYHA) class III or IV, poorly controlled hypertension, recently diagnosed or poorly controlled type 2 diabetes, last known \< 30%, myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG), stroke, planned cardiac surgery or revascularization within 6 months of randomization, uncontrolled cardiac arrhythmia.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.
Other: Placebo
Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.
Other: Placebo
Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
Biological: Evolocumab
Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
Biological: Evolocumab
Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
Biological: Evolocumab
Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
Biological: Evolocumab
Administered by subcutaneous injection
Also known as: AMG 145, Repatha
Administered by subcutaneous injection
Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12
LDL-C was measured using ultracentrifugation.
Time frame: Baseline and Week 12
Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12
LDL-C was measured using ultracentrifugation.
Time frame: Baseline and Week 12
Percentage of Participants With an LDL-C Response at Week 12
An LDL-C response was defined as LDL-C \< 70 mg/dL (1.8 mmol/L) at Week 12. LDL-C was measured using ultracentrifugation.
Time frame: Week 12
Percent Change From Baseline to Week 12 in Non-HDL-C
Time frame: Baseline and Week 12
Percent Change From Baseline to Week 12 in Apolipoprotein B
Time frame: Baseline and Week 12
Percent Change From Baseline to Week 12 in VLDL-C
Time frame: Baseline and Week 12
Percent Change From Baseline to Week 12 in Total Cholesterol/HDL-C Ratio
Time frame: Baseline and Week 12
Percent Change From Baseline to Week 12 in Apolipoprotein B/Apolipoprotein A-1 Ratio
Time frame: Baseline and Week 12
Japanese men or women ≥ 20 to ≤ 80 years of age and who were at high risk for cardiovascular events, on a stable dose of an approved statin (with or without ezetimibe) and fasting low-density lipoprotein cholesterol (LDL-C) ≥ 115 mg/dL. First patient enrolled on 10 July 2012; last patient enrolled 19 February 2013.
| Milestone | Placebo Q2W | Placebo Q4W | Evolocumab 70 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 420 mg Q4W |
|---|---|---|---|---|---|---|
| Started | 52 | 51 | 50 | 52 | 52 | 53 |
| Received treatment | 52 | 50 | 49 | 52 | 51 | 53 |
| Completed | 52 | 50 | 47 | 50 | 51 | 51 |
| Not completed | 0 | 1 | 3 | 2 | 1 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 | 3 | 1 | 0 | 1 |
| Withdrew: Other | 0 | 0 | 0 | 1 | 1 | 1 |
LDL-C was measured using ultracentrifugation.
| percent change | Placebo Q2W | Placebo Q4W | Evolocumab 70 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 420 mg Q4W |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12 | -2.71 ± 2.16 | 0.05 ± 2.32 | -55.56 ± 2.23 | -71.32 ± 2.16 | -58.10 ± 2.33 | -63.89 ± 2.27 |
LDL-C was measured using ultracentrifugation.
| mg/dL | Placebo Q2W | Placebo Q4W | Evolocumab 70 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 420 mg Q4W |
|---|---|---|---|---|---|---|
| Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12 | -1.8 ± 3.6 | 0.8 ± 3.4 | -77.2 ± 3.7 | -98.0 ± 3.6 | -79.9 ± 3.4 | -87.4 ± 3.3 |
An LDL-C response was defined as LDL-C \< 70 mg/dL (1.8 mmol/L) at Week 12. LDL-C was measured using ultracentrifugation.
| percentage of participants | Placebo Q2W | Placebo Q4W | Evolocumab 70 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 420 mg Q4W |
|---|---|---|---|---|---|---|
| Percentage of Participants With an LDL-C Response at Week 12 | 0.0 ± 3.6 | 0.0 ± 3.4 | 66.0 ± 3.7 | 96.0 ± 3.6 | 80.4 ± 3.4 | 82.4 ± 3.3 |
| percent change | Placebo Q2W | Placebo Q4W | Evolocumab 70 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 420 mg Q4W |
|---|---|---|---|---|---|---|
| Percent Change From Baseline to Week 12 in Non-HDL-C | -2.20 ± 1.94 | 0.55 ± 2.17 | -51.66 ± 2.00 | -64.76 ± 1.94 | -53.00 ± 2.17 | -57.53 ± 2.12 |
| percent change | Placebo Q2W | Placebo Q4W | Evolocumab 70 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 420 mg Q4W |
|---|---|---|---|---|---|---|
| Percent Change From Baseline to Week 12 in Apolipoprotein B | -0.90 ± 1.82 | 0.22 ± 2.02 | -47.65 ± 1.88 | -61.59 ± 1.82 | -47.16 ± 2.03 | -53.22 ± 1.98 |
| percent change | Placebo Q2W | Placebo Q4W | Evolocumab 70 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 420 mg Q4W |
|---|---|---|---|---|---|---|
| Percent Change From Baseline to Week 12 in VLDL-C | 8.23 ± 8.55 | 7.26 ± 6.87 | -16.02 ± 8.74 | -26.26 ± 8.44 | -13.56 ± 6.80 | -22.56 ± 6.71 |
| percent change | Placebo Q2W | Placebo Q4W | Evolocumab 70 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 420 mg Q4W |
|---|---|---|---|---|---|---|
| Percent Change From Baseline to Week 12 in Total Cholesterol/HDL-C Ratio | -4.82 ± 1.91 | 1.19 ± 2.09 | -42.04 ± 1.98 | -51.81 ± 1.91 | -44.11 ± 2.10 | -45.47 ± 2.05 |
| percent change | Placebo Q2W | Placebo Q4W | Evolocumab 70 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 420 mg Q4W |
|---|---|---|---|---|---|---|
| Percent Change From Baseline to Week 12 in Apolipoprotein B/Apolipoprotein A-1 Ratio | -3.18 ± 2.12 | 1.44 ± 2.21 | -50.71 ± 2.19 | -64.53 ± 2.12 | -50.79 ± 2.22 | -56.31 ± 2.16 |
Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Q2W | — | 0/52 (0%) | 6/52 (11.5%) |
| Placebo Q4W | — | 0/50 (0%) | 6/50 (12%) |
| Evolocumab Q2W 70 MG | — | 0/49 (0%) | 10/49 (20.4%) |
| Evolocumab Q2W 140 MG | — | 1/52 (1.9%) | 9/52 (17.3%) |
| Evolocumab Q4W 280 MG | — | 1/51 (2%) | 12/51 (23.5%) |
| Evolocumab Q4W 420 MG | — | 2/53 (3.8%) | 8/53 (15.1%) |
| Event | Placebo Q2W | Placebo Q4W | Evolocumab Q2W 70 MG | Evolocumab Q2W 140 MG | Evolocumab Q4W 280 MG | Evolocumab Q4W 420 MG |
|---|---|---|---|---|---|---|
| ArteriosclerosisVascular disorders | 0/52 | 0/50 | 0/49 | 0/52 | 1/51 | 0/53 |
| FractureInjury, poisoning and procedural complications | 0/52 | 0/50 | 0/49 | 1/52 | 0/51 | 0/53 |
| Carcinoid tumour of the caecumNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/52 | 0/50 | 0/49 | 0/52 | 0/51 | 1/53 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/52 | 0/50 | 0/49 | 0/52 | 0/51 | 1/53 |
| Event | Placebo Q2W | Placebo Q4W | Evolocumab Q2W 70 MG | Evolocumab Q2W 140 MG | Evolocumab Q4W 280 MG | Evolocumab Q4W 420 MG |
|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 6/52 | 6/50 | 10/49 | 9/52 | 12/51 | 8/53 |
Full analysis set (all randomized participants who received at least 1 dose of investigational product).
| Age, Continuous(years) | Placebo Q2W | Placebo Q4W | Evolocumab 70 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 420 mg Q4W | Total |
|---|---|---|---|---|---|---|---|
| Mean | 60.2 ± 10.1 | 60.9 ± 9.8 | 64.1 ± 9.7 | 60.8 ± 9.2 | 61.6 ± 9.6 | 61.3 ± 9.9 | 61.5 ± 9.7 |
| Sex: Female, Male(Participants) | Placebo Q2W | Placebo Q4W | Evolocumab 70 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 420 mg Q4W | Total |
|---|---|---|---|---|---|---|---|
| Female | 16 | 14 | 24 | 20 | 23 | 17 | 114 |
| Male | 36 | 36 | 25 | 32 | 28 | 36 | 193 |
| Race/Ethnicity, Customized(participants) | Placebo Q2W | Placebo Q4W | Evolocumab 70 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 420 mg Q4W | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 52 | 50 | 49 | 52 | 51 | 53 | 307 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stratification Factor: LDL Level(participants) | Placebo Q2W | Placebo Q4W | Evolocumab 70 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 420 mg Q4W | Total |
|---|---|---|---|---|---|---|---|
| < 130 mg/dL | 17 | 17 | 15 | 17 | 15 | 17 | 98 |
| ≥ 130 mg/dL | 35 | 33 | 34 | 35 | 36 | 36 | 209 |
| Stratification Factor: Diagnosis of Heterozygous Familial Hypercholesterolemia (HeFH)(participants) | Placebo Q2W | Placebo Q4W | Evolocumab 70 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 420 mg Q4W | Total |
|---|---|---|---|---|---|---|---|
| No | 48 | 47 | 47 | 49 | 47 | 49 | 287 |
| Yes | 4 | 3 | 2 | 3 | 4 | 4 | 20 |
| LDL-C Concentration(mg/dL) | Placebo Q2W | Placebo Q4W | Evolocumab 70 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 420 mg Q4W | Total |
|---|---|---|---|---|---|---|---|
| Mean | 144.4 ± 18.1 | 141.8 ± 23.4 | 143.6 ± 20.6 | 140.7 ± 23.3 | 141.0 ± 21.2 | 139.7 ± 18.8 | 141.8 ± 20.9 |
| Non-High-Density Lipoprotein Cholesterol (non-HDL-C) Concentration(mg/dL) | Placebo Q2W | Placebo Q4W | Evolocumab 70 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 420 mg Q4W | Total |
|---|---|---|---|---|---|---|---|
| Mean | 171.3 ± 23.0 | 168.7 ± 26.1 | 170.6 ± 27.2 | 166.3 ± 26.2 | 165.5 ± 24.4 | 166.7 ± 23.5 | 168.2 ± 25.0 |
| Apolipoprotein B Concentration(mg/dL) | Placebo Q2W | Placebo Q4W | Evolocumab 70 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 420 mg Q4W | Total |
|---|---|---|---|---|---|---|---|
| Mean | 114.6 ± 15.4 | 112.5 ± 16.6 | 113.1 ± 19.2 | 109.4 ± 16.0 | 109.6 ± 16.9 | 109.8 ± 15.9 | 111.5 ± 16.7 |
3 further baseline measures are reported on the registry.
Ran from Jul 2012 to primary completion in May 2013, 10 months.
Results were first posted in Oct 2015, 2 years 4 months after primary completion. A results delay was requested in May 2014.
Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 10 months is above that.
Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evolocumab